QNTM — Quantum Biopharma Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1771885 ·
Ontario, Canada
Last close
$1.59
Market Cap
$10.22M
52W High
$12.42
52W Low
$1.33
ADV30
108,761
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -2,281,086 | -3,252,967 | 14,391,885 | 3,647,072 | 8,297,670 |
| Mar 2026 | 0 | — | -2,909,492 | -13,560,299 | 14,926,075 | 4,341,908 | 16,345,974 |
| Dec 2025 | 0 | — | -2,359,801 | -3,026,467 | 11,160,909 | 1,905,357 | 6,058,294 |
| Sep 2025 | 0 | — | -4,658,195 | -5,319,029 | 14,153,228 | 445,944 | 6,646,480 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-5,485,545
Investing CF
$-3,498,569
Financing CF
$11,133,610
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-8.01
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-215,099,436
Inventory
$53,012
Receivables
$107,634
ST Investments
$210,708
EBIT TTM
$-24,980,343
Pretax Income TTM
$-25,297,132
Interest Exp TTM
$316,789
Analysts
1
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -15,317,409 | -26,175,286 | 11,160,909 | 6,058,294 | 6,924,475 | -8,237,012 |
| Dec 2024 | 0 | -15,884,034 | -14,202,724 | 17,119,224 | 6,678,992 | 11,480,538 | -6,876,479 |
| Dec 2023 | 0 | -19,570,114 | -17,902,179 | 17,474,828 | 4,565,566 | 13,236,763 | -10,827,264 |
| Dec 2022 | 0 | -27,429,611 | -23,606,828 | 38,410,656 | 7,868,436 | 30,542,220 | -28,333,273 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-7.80
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals, Inc. | $10.38M | $0.12 | — |
| RADX | Radiopharm Theranostics Ltd | $9.70M | $0.67 | — |
| HIND | Vyome Holdings, Inc | $10.84M | $1.54 | — |
| BIVI | BIOVIE INC. | $9.61M | $1.00 | — |
| PBM | PSYENCE BIOMEDICAL LTD. | $9.57M | $2.51 | — |
News headlines (Yahoo Finance, 1h cache)
Quantum BioPharma (QNTM) Reports $12.22M in Cash and Digital Assets, Advances Lucid-MS Phase 2 Trial
2026-11-16 19:29 · Yahoo
Quantum BioPharma achieve 91% increase in Shareholder Equity and Liquidity in Q3 2026 as Lucid-MS Phase 2 Trial Advances into Study Start-Up
2026-11-13 12:05 · Yahoo
Quantum BioPharma (QNTM) Reports Shareholder Meeting Results, Closes Private Placement Increasing Insider Voting Control
2026-11-11 20:30 · Yahoo
Quantum BioPharma Announces Results of Annual General and Special Meeting of Shareholders and Closing of Private Placement of Class A Multiple Voting Shares
2026-11-11 12:07 · Yahoo
Quantum BioPharma Ltd. Announces Filing of Supplement to Management Information Circular Correcting Fractional Share Treatment Under Proposed Share Consolidation and Clarifies MVS Voting Power Thresho
2026-11-05 22:00 · Yahoo
Quantum BioPharma (QNTM) Advances Broad Strategy Anchored by Science, Disciplined Growth
2026-11-05 20:00 · Yahoo
Quantum BioPharma (QNTM) Draws 'Men's Fitness' Spotlight as Unbuzzd Trial Shows Early Promise
2026-11-03 20:30 · Yahoo
World Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum B
2026-10-08 12:00 · Yahoo
Quantum BioPharma (QNTM) Enlists Thermo Fisher's Clinical Research Business to Launch Phase 2 Lucid-MS Trial
2026-10-07 19:30 · Yahoo
Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis
2026-10-06 10:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.